Regeneron reports first quarter 2022 financial and operating results

Tarrytown, n.y. , may 4, 2022 /prnewswire/ -- first quarter 2022 revenues increased 17% to $2.97 billion versus first quarter 2021; excluding regen-cov ® (a)(b), revenues increased 25% first quarter 2022 eylea® u.s. net sales increased 13% to $1.52 billion versus first quarter 2021 first quarter 2022 dupixent® global net sales(c)(recorded by sanofi) increased 43% to $1.81 billion versus first quarter 2021 first quarter 2022 gaap diluted eps of $8.61; non-gaap diluted eps(a) of $11.49 dupixent approved in eu for children aged 6–11 years with severe asthma; fda priority review granted for atopic dermatitis in children aged 6 months to 5 years and eosinophilic esophagitis regeneron pharmaceuticals, inc. (nasdaq: regn) today announced financial results for the first quarter of 2022 and provided a business update.
REGN Ratings Summary
REGN Quant Ranking